Natural products—such as taxol, artemisinin, and various polyphenols—are critical components in modern pharmaceuticals, nutraceuticals, and agrochemicals. Historically, their extraction relied on plant biomass, a method that is often non-scalable, subject to geographical variability, and requires harsh chemical processing that can degrade sensitive molecules. Furthermore, the complex biosynthesis pathways within plants are difficult to replicate or optimize for industrial yield. Bioprocess engineering offers a sustainable alternative by leveraging biological systems (microorganisms, fungi, or plant cell cultures) as “mini-factories” to synthesize these high-value compounds efficiently and under mild conditions. The core challenge, therefore, lies in transitioning complex, low-yield biological pathways into robust, scalable, and economically viable industrial processes.
The bioprocess mechanism centers on metabolic engineering, which involves the rational redesign of a host organism’s metabolism to overproduce a target compound. This process begins with pathway identification, requiring the elucidation of the complete biosynthetic pathway and the identification of all necessary genes and enzymes (e.g., polyketide synthases, terpene cyclases, or specific oxidoreductases). Since the chosen host organism (such as *Saccharomyces cerevisiae* or *E. coli*) may not naturally possess the required pathway, the genes are transferred into the host’s genome via heterologous expression, ensuring continuous and stable enzyme production.
To maximize metabolic flux toward the desired product, the pathway must be rigorously optimized. Optimization strategies include gene overexpression, which increases the copy number or transcription rate of rate-limiting enzymes; cofactor balancing, which ensures a sufficient supply of essential cofactors like NADPH and ATP to prevent metabolic bottlenecks; and toxicity mitigation, which engineers the host to handle accumulating products. The overall mechanism is thus a controlled, enzymatic cascade occurring within the engineered cell, converting simple, inexpensive feedstocks (like glucose or glycerol) into complex, high-value molecules.
Translating a successful laboratory-scale fermentation into a commercial bioprocess requires addressing several critical engineering challenges. Bioreactor design and control are paramount, necessitating large-scale bioreactors with precise control over physicochemical parameters. Maintaining stable pH and temperature is crucial for enzyme stability and optimal microbial growth kinetics. Furthermore, since many biosynthetic pathways are highly aerobic, efficient sparging and agitation must be employed to maintain adequate dissolved oxygen transfer rates ($k_L a$). Implementing fed-batch culture strategies is also essential to prevent substrate inhibition and manage osmotic stress.
Following fermentation, the efficiency of downstream processing (DSP) dictates the overall cost of goods (CoG). Techniques employed for product isolation include liquid-liquid extraction, adsorption chromatography using specialized resins, or crystallization. These methods are necessary to purify the target molecule to pharmaceutical or industrial grade. Future advancements focus heavily on process intensification, particularly continuous flow bioprocessing and enzyme/cell immobilization. Immobilizing the engineered cells or enzymes onto solid supports allows for continuous operation, improved operational stability, and easier separation, significantly enhancing the throughput and economic efficiency of the bioprocess.